pactimibe
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2002 (NCT00185146)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Acyl-coenzyme A thioesterase 1INHIBITOR
ACOT1 inhibitor
Acyl coenzyme A:cholesterol acyltransferase 1 inhibitor
Acyl coenzyme A:cholesterol acyltransferase 2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21- Mol. weight
- 416.61 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL478858 ↗
Also known as
- (7-(2,2-dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid hemisulfate
- cs-505
- pactimibe
- pactimibe
- pactimibe
- pactimibe
- pactimibe
- pactimibe sulfate
- pactimibe sulfate
- pactimibe sulfate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00151788 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2004 | Daiichi Sankyo |
| NCT00185042 | Phase 2 | Nov 1, 2002 | Daiichi Sankyo |
| NCT00185146 | Phase 2 | Sep 1, 2002 | IMFORM GmbH, Sankyo |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 2 | 2 | 2 | 2002 |
| IMFORM GmbH | For profit | 1 | 0 | 1 | 2002 |
| Sankyo | For profit | 1 | 1 | 1 | 2002 |
3 organizations
Page 1 / 1